Stabilized bioactive peptides and methods of identification, synthesis, and use
View Patent ↗An intracellular selection system allows screening for peptide bioactivity and stability. Randomized recombinant peptides are screened for bioactivity in a tightly regulated expression system, preferably derived from the wild-type lac operon. Bioactive peptides thus identified are inherently protease- and peptidase-resistant. Also provided are bioactive peptides stabilized by a stabilizing group at the N-terminus, the C-terminus, or both. The stabilizing group can be a small stable protein, such as the Rop protein, glutathione sulfotransferase, thioredoxin, maltose binding protein, or glutathione reductase, an α-helical moiety, or one or more proline residues.
1. A polypeptide comprising a bioactive peptide and a first stabilizing group covalently linked to an N-terminus or C-terminus of said bioactive peptide, wherein the bioactive peptide is a therapeutic peptide selected from the group consisting of insulin, glucagon, calcitonin, somatostatin, gonadotrophin, secretin, angiotensin II, bradykinin, caerulein, cholecystokinin, corticotropin, eledoisin, gastrin, gramicidin D, kallidin, luteinizing hormone-releasing factor, melittin, oxytocin, sermorelin, and vasopressin; and wherein said first stabilizing group is heterologous to the bioactive peptide, lacks the capacity to participate in the formation of an intramolecular disulfide bond within the polypeptide, and comprises an α-helical moiety selected from the group consisting of a single α-helix, a two-helix bundle a three-helix bundle, and a five-helix bundle.
2. A polypeptide comprising a bioactive peptide and a first stabilizing group covalently linked to an N-terminus or C-terminus of said bioactive peptide. wherein the bioactive peptide is a therapeutic peptide selected from the group consisting of insulin, glucagon, calcitonin, somatostatin, gonadotrophin, secretin, angiotensin II, bradykinin, caerulein, cholecystokinin, corticotropin, in eledoisin, gastrin, gramicidin D kallidin, luteinizing hormone-releasing factor, melittin, oxytocin, sermorelin, and vasopressin; and wherein said first stabilizing group is heterologous to the bioactive peptide and is Ala-Pro-Pro- or -Pro-Pro-Ala.
3. A polypeptide comprising a bioactive peptide, a first stabilizing group covalently linked to an N-terminus or C-terminus of said bioactive peptide, and a second stabilizing group covalently linked to the other terminus of said bioactive peptide; wherein the bioactive peptide is a therapeutic peptide selected from the group consisting of insulin, glucagon, calcitonin, somatostatin, gonadotrophin, secretin, angiotensin II, bradykinin, caerulein, cholecystokinin, corticotropin, eledoisin, gastrin, gramicidin D, kallidin, luteinizing hormone-releasing factor, melittin, oxytocin, sermorelin, and vasopressin; wherein said first stabilizing group is heterologous to the bioactive peptide and lacks the capacity to participate in the formation of an intramolecular disulfide bond within the polypeptide; and wherein said second stabilizing group is heterologous to the bioactive peptide and comprises an α-helical moiety selected from the group consisting of a single α-helix, a two-helix bundle a three-helix bundle, and a five-helix bundle.
4. A polypeptide comprising a bioactive peptide and a first stabilizing group covalently linked to an N-terminus or C-terminus of said bioactive peptide, wherein said first stabilizing group is heterologous to the bioactive peptide and consists essentially of an α-helical moiety selected from the group consisting of a single α-helix, a two-helix bundle, a three-helix bundle, and a five-helix bundle.
5. The polypeptide of claim 4 , wherein said polypeptide further comprises a second stabilizing group covalently linked to the other terminus of said bioactive peptide, wherein the second stabilizing group is heterologous to the bioactive peptide.
6. The polypeptide of claim 5 , wherein said first and said second stabilizing groups are the same.
7. The polypeptide of claim 5 , wherein said second stabilizing group is Xaa-Pro-Pro- or -Pro-Pro-Xaa, wherein Xaa is any amino acid.
8. The polypeptide of claim 7 , wherein Xaa is Ala.
9. The polypeptide of claim 5 , wherein said second stabilizing group consists essentially of an α-helical moiety selected from the group consisting of a single α-helix, a two-helix bundle a three-helix bundle, and a five-helix bundle.
10. The polypeptide of claim 4 , wherein said first stabilizing group is covalently linked to the N-terminus of said bioactive peptide.
11. The polypeptide of claim 4 , wherein said first stabilizing group is covalently linked to the C-terminus of said bioactive peptide.
12. The polypeptide of claim 4 , wherein said bioactive peptide is selected from the group consisting of insulin, glucagon, calcitonin, somatostatin, gonadotrophin, secretin, angiotensin II, bradykinin, caerulein, cholecystokinin, corticotropin, eledoisin, gastrin, gramicidin D, kallidin, luteinizing hormone-releasing factor, melittin, oxytocin, sermorelin, and vasopressin.
13. The polypeptide of claim 4 , wherein the α-helical moiety is a single α-helix.
14. The polypeptide of claim 4 , wherein the α-helical moiety is a two-helix bundle.
15. The polypeptide of claim 4 , wherein the α-helical moiety is a three-helix bundle.
16. The polypeptide of claim 4 , wherein the α-helical moiety is a five-helix bundle.
17. The polypeptide of claim 4 , wherein said bioactive peptide is 5 to 20 amino acids in length.
18. A polypeptide comprising a bioactive peptide, a first stabilizing group covalently linked to the N-terminus of said bioactive peptide and a second stabilizing group covalently linked to the C-terminus of said bioactive peptide, wherein said first and second stabilizing groups are heterologous to the bioactive peptide and to each other, and wherein the first stabilizing group consists essentially of an α-helical moiety selected from the group consisting of a single α-helix, a two-helix bundle a three-helix bundle, and a five-helix bundle.
19. A polypeptide comprising a bioactive peptide, a first stabilizing group covalently linked to the N-terminus of said bioactive peptide and a second stabilizing group covalently linked to the C-terminus of said bioactive peptide, wherein said first and second stabilizing groups are heterologous to the bioactive peptide and do not interact to form a naturally occurring secondary or tertiary structure, and wherein the first stabilizing group consists essentially of an α-helical moiety selected from the group consisting of a single α-helix, a two-helix bundle a three-helix bundle, and a five-helix bundle.
20. A polypeptide comprising a bioactive peptide, a first stabilizing group covalently linked to the N-terminus of said bioactive peptide and a second stabilizing group covalently linked to the C-terminus of said bioactive peptide, wherein said first stabilizing group and second groups are heterologous to the bioactive peptide and do not confine the N-terminus and the C-terminus of the bioactive peptide in close proximity, and wherein the first stabilizing group consists essentially of an α-helical moiety selected from the group consisting of a single α-helix, a two-helix bundle a three-helix bundle, and a five-helix bundle.
21. A polypeptide comprising a bioactive peptide and a first stabilizing group covalently linked to an N-terminus or C-terminus of said bioactive peptide, said bioactive peptide having been identified using a phage display process that produces a bacteriophage protein covalently linked to an N- or C-terminus of said bioactive peptide, wherein the stabilizing group takes the place of the bacteriophage protein, and wherein the stabilizing group consists essentially of an α-helical moiety selected from the group consisting of a single α-helix, a two-helix bundle a three-helix bundle, and a five-helix bundle.